 | A major contributor to this article appears to have aclose connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularlyneutral point of view. Please discuss further on thetalk page.(September 2021) (Learn how and when to remove this message) |
 | |
 Fortis Hospital, Noida | |
| Company type | Public |
|---|---|
| BSE: 532843 NSE: FORTIS | |
| Industry | Healthcare |
| Founded | 1996; 29 years ago (1996) |
| Headquarters | , India |
Area served | Worldwide |
Key people | Ravi Rajagopal(Chairman)[1] |
| Products | Hospitals,Pharmacy,Diagnostic centres |
| Revenue |  ₹7,783 crore (US$920 million) (2025) |
| ₹1,588 crore (US$190 million) (2025) | |
| ₹809 crore (US$96 million) (2025) | |
| Owner | IHH Healthcare (31.1%) |
Number of employees | 23,000 (2023) |
| Subsidiaries | Agilus Diagnostics |
| Website | www |
| Footnotes / references Financials as of 31 March 2025[update].[2] | |
Fortis Healthcare Limited is an Indianfor-profitprivatehospital network headquartered inGurgaon.
The Fortis Memorial Research Institute (FMRI) inGurgaon serves as the headquarters for Fortis Healthcare.[3][4] In addition to its Gurgaon facility, Fortis Healthcare operates hospitals in theDelhiNCR, including locations inFaridabad,Noida,Vasant Kunj, andShalimar Bagh, along with other facilities across India,Dubai, andSri Lanka. The company currently[when?] manages 36 healthcare facilities.[5][6]
Fortis Healthcare was founded in 1996 as an offshoot of the pharmaceutical companyRanbaxy Laboratories.[7] It began operating inMohali,Punjab, where its first hospital was established. It later expanded by acquiring the healthcare division ofEscorts Group, including the Escorts Heart and Research Center,Okhla,Delhi.[8]
In February 2018, foundersMalvinder Singh andShivinder Singh resigned from the board of Fortis Healthcare following allegations that they had siphoned $78 million out of the company. A month earlier, theDelhi High Court had upheld a 2016 Singapore arbitration tribunal order against the Singh brothers to pay₹3,500 crore ($550 million) in damages toDaiichi Sankyo for misrepresenting information during the sale ofRanbaxy Laboratories.[9][10]
In March 2018,Manipal Hospitals andTPG Capital offered to buy out Singh brothers' stake in Fortis Healthcare for₹3,900 crore.[11][12][13] After a bidding war,[14] Malaysia'sIHH Healthcare completed the acquisition of a 31.1% controlling stake for₹4,000 crore. Representatives from IHH Healthcare were appointed to the board of Fortis.[15] Later that year, IHH Healthcare halted itstender offer to buy an additional 26% stake from public shareholders after theSupreme Court ordered a status quo in response to Daiichi Sankyo'scontempt plea against the Singh brothers over the stake sale.[16]
In 2019, Fortis Healthcare announced the acquisition of RHT Health Trust (RHT) assets for an enterprise value of₹4,650 crore.[17]
In August 2023, Fortis announced the completion of its acquisition ofMedeor Hospital inManesar fromVPS Healthcare for $27.23 million.[18]
In 2024, Fortis Healthcare announced that it would acquire a 31% stake held byprivate equity firms in its diagnostics subsidiary,Agilus Diagnostics, for₹1,780 crore.[19]
